

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

BHT-101

RRID:CVCL_1085

Type: Cell Line

Proper Citation

RRID:CVCL_1085

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1085

Proper Citation: RRID:CVCL_1085

Description: Cell line BHT-101 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Thyroid gland anaplastic carcinoma

Defining Citation: [PMID:8099464](#), [PMID:18713817](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23833040](#), [PMID:27397505](#), [PMID:30737244](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BHT-101

Synonyms: BHT101

Cross References: BTO:BTO_0002274, CLO:CLO_0001974, EFO:EFO_0002116, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473340, BioSample:SAMN10988574, cancercellines:CVCL_1085, CCRID:3101HUMSCSP544, Cell_Model_Passport:SIDM00987, ChEMBL-Cells:ChEMBL3308096, ChEMBL-Targets:ChEMBL1075398, CLS:305112, Cosmic:891255, Cosmic:906696, Cosmic:1162841, Cosmic:1239963, Cosmic:2054079, Cosmic:2613250, Cosmic-CLP:906696, DepMap:ACH-000191, DSMZ:ACC-279, DSMZCellDive:ACC-279,

EGA:EGAS00001000978, GDSC:906696, GEO:GSM886881, GEO:GSM887946, GEO:GSM1669619, IARC_TP53:21193, IGRhCellID:BHT101, LiGeA:CCLE_885, LINCS_LDP:LCL-1688, PharmacDB:BHT101_91_2019, PRIDE:PXD030304, Progenetix:CVCL_1085, PubChem_Cell_line:CVCL_1085, Wikidata:Q54796508

ID: CVCL_1085

Record Creation Time: 20220427T215401+0000

Record Last Update: 20260905T185020+0000

Ratings and Alerts

No rating or validation information has been found for BHT-101.

No alerts have been found for BHT-101.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Jiang L, et al. (2026) Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(7), 1313.

Huo Y, et al. (2026) FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell-Mediated Antitumor Immunity. Cancer research, 86(9), 2184.

Zhou R, et al. (2026) DNMT2 inhibits anaplastic thyroid cancer progression by downregulating 5'tiRNAGly-GCC production. Cell death & disease, 17(1).

Han Y, et al. (2025) TGF- β 1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs. Molecular therapy : the journal of the American Society of Gene Therapy, 33(12), 6130.

Lundgren Mortensen AC, et al. (2025) Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts. Molecular cancer therapeutics, 24(5), 753.

Xu B, et al. (2023) Pan cancer characterization of genes whose expression has been associated with LINE-1 antisense promoter activity. Mobile DNA, 14(1), 13.

Zhang Y, et al. (2022) ZHX2 inhibits thyroid cancer metastasis through transcriptional inhibition of S100A14. *Cancer cell international*, 22(1), 76.

Zhan S, et al. (2022) Asporin Interacts With HER2 to Promote Thyroid Cancer Metastasis via the MAPK/EMT Signaling Pathway. *Frontiers in oncology*, 12, 762180.

Marlow LA, et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. *The Journal of clinical endocrinology and metabolism*, 103(9), 3169.